Ovarian cancer and gynecologic oncology
Tubulis GmbH focuses on high-grade epithelial ovarian cancer, including platinum-resistant ovarian cancer and therapy-resistant ovarian malignancies. Its clinical research includes targeted approaches for women with advanced disease and combinations with standard chemotherapy in ovarian cancer.
- High-grade serous ovarian cancer
- Endometrioid epithelial ovarian cancer
- Platinum-resistant ovarian cancer
- Therapy-resistant ovarian cancer
The sponsor’s work in this area centers on targeted oncology for difficult-to-treat ovarian tumors.
Non-small-cell lung cancer
The company is also active in non-small-cell lung cancer, including relapsed/refractory adenocarcinoma and advanced metastatic lung cancer. These studies address patients with limited treatment options and emphasize disease settings with persistent tumor burden.
- Relapsed/refractory NSCLC
- Adenocarcinoma of the lung
- Advanced metastatic solid tumors
Its research portfolio in lung cancer reflects interest in targeted treatment strategies for solid tumors with unmet clinical need.
Head and neck squamous cell carcinoma
Tubulis GmbH includes head and neck squamous cell carcinoma among its active oncology areas, with studies in patients who have advanced or metastatic tumors. This indicates attention to aggressive epithelial cancers beyond the more common thoracic and gynecologic settings.
- Advanced HNSCC
- Metastatic epithelial tumors
- Refractory solid tumors
The sponsor’s clinical activity in this domain is aligned with precision oncology for difficult squamous cell malignancies.
Antibody-guided drug delivery and targeted therapeutics
Across its trials, the sponsor investigates antibody-guided drug delivery and other targeted cancer therapies designed for solid tumors. The research includes agents such as TUB-030 and TUB-040, with clinical interest in safety, tolerability, and early antitumor activity in advanced malignancies.
- Targeted drug delivery
- Antibody-drug conjugate development
- Early oncology development
This area highlights a focus on novel oncology platforms for advanced solid tumors.
